XOMA Corporation XOMA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Income Not From Contract With Customer Cost Recovery Method by Product | ||||||
| Tovorafenib | $2.77M-49.9% | $4.62M+258% | $1.86M+78.6% | $1.72M+97.1% | $5.53M— | |
| Income Not From Contract With Customer Effective Interest Rate Method by Product | ||||||
| Ixinity | $246K-2.8% | $248K+273% | $239K+259% | $249K+274% | $253K+280% | |
| Miplyffa | $2.3M+411% | $450K— | $450K— | $450K— | $450K— | |
| Vabysmo | $6.7M+15.1% | $5.66M+17.5% | $6.72M+24.0% | $5.76M+26.2% | $5.82M— | |
| Rights Receivable Eir Method Receipt Of Payments by Product | ||||||
| Ixinity | $479K-14.6% | $406K— | $388K— | $369K— | $561K— | |
| Miplyffa | $1.07M+371% | $227K— | $227K— | $227K— | $227K— | |
| Vabysmo | $11.95M+7.2% | —— | $11.36M— | —— | $11.15M— | |
| Rights Receivable Eir Method Payment Of Sales Based Milestones by Product | ||||||
| Ixinity | $5.66M— | —— | —— | —— | —— | |
| Miplyffa | $4.99M— | —— | —— | —— | —— | |
| Vabysmo | $12.31M+310% | —— | —— | —— | $3M— | |
| Revenue by Geography | ||||||
| CH | $6.7M+15.1% | $5.66M+17.6% | $6.72M+24.0% | $5.76M+87.4% | $5.82M+290% | |
| US | $5.62M-7.8% | $7M+208% | $2.63M+48.1% | $7.37M+13.0% | $6.1M+309% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does XOMA Corporation break its business down?
- XOMA Corporation (XOMA) reports income not from contract with customer cost recovery method by product across 2 parts — Dsuvia and Tovorafenib. Each is extracted from the segment footnotes and tracked over time.
- Where does XOMA Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in XOMA Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
